Lupin bags Health Canada nod for biosimilar Pegfilgrastim
Armlupeg is available in a form of pre-filled syringe of 6mg/0.6 ml.
Mumbai: Global pharma major Lupin Limited has announced that the Company has received approval from Health Canada for its biosimilar Pegfilgrastim. This product will be marketed under the brand name Armlupeg and manufactured at Lupin’s Biotech facility at Pune, India.
Armlupeg (pegfilgrastim) is a biosimilar comparable to the reference biologic drug NEULASTA (pegfilgrastim). Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim. Pegfilgrastim prefilled syringes are indicated to decrease the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.
Armlupeg is available in a form of pre-filled syringe of 6mg/0.6 ml.
Nilesh Gupta, Managing Director, Lupin said, “We are committed to providing affordable and high-quality treatment to our patients. The Health Canada approval for Armlupeg strengthens our ability to support Canadian patients with this mainstay treatment.”
Read also: Lupin alliance partner ForDoz gets USFDA nod for Doxorubicin Hydrochloride Liposome Injection
Dr. Cyrus Karkaria, President, Biotech Division said, “Biosimilars play an important role providing access to cancer treatment and supportive care. We are happy to receive our second biosimilar approval in Canada and look forward to maintaining this momentum with additional launches in regulated markets.”
Read also: Lupin, Huons ink pact for registration, marketing of Cyclosporine Ophthalmic Nanoemulsion in Mexico
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. The company has strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally. Lupin subsidiaries are Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Read also: Lupin secures USFDA tentative nod for Brimonidine Tartrate Ophthalmic Solution
